Mimedx Group Inc (MDXG) Stock Price, Quote & News

Company Profile

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techni...

Industry: Biotechnology

Sector: Healthcare

Phone: 770 651 9100

Website: www.mimedx.com

Address:

1775 West Oak Commons Court, NE, Marietta, United States

MrStealYourShares Dec. 6 at 2:09 AM

$MDXG closed my dec19 covered calls at 85% gain. I have basically lowered my cost basis by 40% with the gains from the covered calls this year. Rolled them out another 100 days or so. Orders still at $5 and $6 and will keep doing this until I get assigned.

0 · Reply

Omstapocus Dec. 5 at 3:31 PM

$MDXG As we all know the Cassidy-Carter bill , that is intended to eliminate price gouging practices by skin substitute companies was introduced in July. Although it has been read twice in committee, it still remains there .There is no indication that it is on the December schedule. In addition, since the Affordable Care Act subsidizes are a responsibility of the same committee,this observer doubts that the former bill will receive priority.If that’s the case, the price per square centimeter set by CMS that is clearly low is devastatingly low for the $3000 sq/cm gouges.I think despite the lower price for MDXG, and given the superiority of the product, revenue will be made up in volume especially if CMS reduces the playing field in January to only entities who have demonstrated statistically beneficial results. Since this is now a waiting game, it is not surprising that the stock is flat. Besides, the only stock price important is the one if and when MDXG is bought. Happy Holidays

3 · Reply

RUDYRUDY Dec. 4 at 4:31 PM

$MDXG 16 days till Congres goes home. Now or never for Cassidy/Carter skin sub bills.

1 · Reply

RUDYRUDY Dec. 3 at 9:13 PM

$MDXG Dec 20, Congress shuts down. Race is on for Cassidy/Carter bills.

0 · Reply

SuperGreenToday Dec. 3 at 11:04 AM

$MDXG Share Price: $6.72 Contract Selected: Jun 18, 2026 $10 Calls Buy Zone: $0.54 – $0.66 Target Zone: $1.01 – $1.24 Potential Upside: 79% ROI Time to Expiration: 196 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

ta99bobotw Dec. 2 at 2:54 PM

$MDXG ... the market doesn't seem to be all that optimistic about MDXG taking market share starting in January. Was hoping we'd have seen a bit of price increase by now in anticipation.

2 · Reply

BEATOFtheMARKET Dec. 2 at 2:32 AM

$MDB $MDBX $MDXG $MEC $MEDP

0 · Reply

biomaster22 Dec. 2 at 1:00 AM

$MDXG what does any of the recents posts have to do with the disgraceful share valuation of mdxg nobody should be rewarded, they should be shown the door ! Worst investment the last two years and counting

2 · Reply

RUDYRUDY Dec. 1 at 11:13 PM

$MDXG Stuck in bad chart-ville again. Sheesh.

0 · Reply

GlobalInsights Dec. 1 at 8:52 PM

$MDXG Part 2. The PSUs will vest over a four year performance period ending December 31, 2026 based upon the achievement of specified performance conditions, subject to Mr. Capper’s continued employment except in the case of Mr. Capper’s death or disability. Vesting of PSUs will accelerate upon a deemed termination of employment without Cause upon a Change in Control of the Company occurring prior to the end of the performance period and while Mr. Capper is in continuous service as follows: if Mr. Capper has been in the Company’s employment for at least one year prior to the Change in Control, the PSUs will vest, measured at target (or actual performance, if higher), and if Mr. Capper has been employed for less than one year the PSUs will vest pro-rata based on the number of days employed in relation to the performance period, measured at target (or actual performance, if higher).

0 · Reply

MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial

Nov 10, 2025, 4:01 PM EST - 26 days ago

MIMEDX to Participate in Upcoming Investor Conferences

Nov 4, 2025, 9:56 AM EST - 4 weeks ago

MiMedx: Breakout Setup Into A Policy Overhaul

Nov 3, 2025, 9:15 AM EST - 4 weeks ago

MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule

Oct 29, 2025, 6:56 PM EDT - 5 weeks ago

MiMedx Group, Inc. (MDXG) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 4:01 PM EDT - 5 weeks ago

MIMEDX Announces Record Revenue for Third Quarter 2025

Oct 15, 2025, 8:00 AM EDT - 7 weeks ago

MIMEDX to Host Third Quarter 2025 Operating and Financial Results Conference Call on October 29

Oct 6, 2025, 9:28 AM EDT - 2 months ago

MIMEDX Announces Launch of EPIXPRESS®

Sep 3, 2025, 8:00 AM EDT - 3 months ago

MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) Fall

Jul 30, 2025, 11:01 PM EDT - 4 months ago

MiMedx Group, Inc. (MDXG) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 4:01 PM EDT - 4 months ago

MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results

Jul 30, 2025, 8:00 AM EDT - 4 months ago

MIMEDX Announces Strategic Collaboration with Vaporox, Inc.

Jul 16, 2025, 8:00 AM EDT - 5 months ago

MIMEDX to Host Second Quarter 2025 Operating and Financial Results Conference Call on July 30

Jul 15, 2025, 9:15 AM EDT - 5 months ago

MIMEDX Comments on Proposed Medicare Reimbursement Rule Changes for CY 2026

May 6, 2025, 8:00 AM EDT - 7 months ago

MIMEDX to Present at the BofA Securities 2025 Healthcare Conference

May 5, 2025, 8:30 AM EDT - 7 months ago

MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)

Apr 30, 2025, 9:52 PM EDT - 7 months ago

MiMedx Group, Inc. (MDXG) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 4:01 PM EDT - 7 months ago

MIMEDX Announces First Quarter 2025 Operating and Financial Results

Apr 10, 2025, 4:01 PM EDT - 8 months ago

MIMEDX to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences

Feb 27, 2025, 8:00 AM EST - 10 months ago

MIMEDX to Present at TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 10:50 PM EST - 10 months ago

MiMedx Group, Inc. (MDXG) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:01 PM EST - 10 months ago

MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results

Nov 14, 2024, 9:15 AM EST - 1 year ago

MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs

Oct 30, 2024, 9:38 PM EDT - 1 year ago

MiMedx Group, Inc. (MDXG) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 4:01 PM EDT - 1 year ago

MIMEDX Announces Third Quarter 2024 Operating and Financial Results

Oct 14, 2024, 8:00 AM EDT - 1 year ago

MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30

Oct 8, 2024, 4:01 PM EDT - 1 year ago

MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue

Oct 1, 2024, 4:01 PM EDT - 1 year ago

MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall

Sep 11, 2024, 1:03 PM EDT - 1 year ago

EX-MiMEDX EMPLOYEES ALLEGE MiMEDX "PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR UNSUITABLE PRODUCTS"

Sep 4, 2024, 4:23 PM EDT - 1 year ago

THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'

Aug 26, 2024, 9:30 AM EDT - 1 year ago

DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT

Jul 31, 2024, 9:10 PM EDT - 1 year ago

MiMedx Group, Inc. (MDXG) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 4:02 PM EDT - 1 year ago

MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix

Jul 31, 2024, 4:01 PM EDT - 1 year ago

MIMEDX Announces Second Quarter 2024 Operating and Financial Results

Jul 22, 2024, 8:10 AM EDT - 1 year ago

MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports

Jun 26, 2024, 4:01 PM EDT - 1 year ago

MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer

Apr 30, 2024, 9:33 PM EDT - 1 year ago

MiMedx Group, Inc. (MDXG) Q1 2024 Earnings Call Transcript

Apr 30, 2024, 4:01 PM EDT - 1 year ago

MIMEDX Announces First Quarter 2024 Operating and Financial Results

Apr 16, 2024, 8:00 AM EDT - 1 year ago

MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30

Mar 20, 2024, 7:00 AM EDT - 1 year ago

MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing

Feb 28, 2024, 8:46 PM EST - 1 year ago

MiMedx Group, Inc. (MDXG) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 4:01 PM EST - 1 year ago

MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results

Feb 20, 2024, 8:00 AM EST - 1 year ago

MIMEDX to Present at TD Cowen 44th Annual Health Care Conference

Feb 12, 2024, 8:00 AM EST - 1 year ago

MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28

Jan 22, 2024, 8:00 AM EST - 2 years ago

MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing

Jan 12, 2024, 4:00 PM EST - 2 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors

Jan 11, 2024, 12:54 PM EST - 2 years ago

The Law Offices of Frank R. Cruz Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors

Dec 29, 2023, 7:01 PM EST - 2 years ago

MiMedx reports US FDA warning letter for Axiofill, shares drop

MrStealYourShares Dec. 6 at 2:09 AM

0 · Reply

Omstapocus Dec. 5 at 3:31 PM

3 · Reply

RUDYRUDY Dec. 4 at 4:31 PM

$MDXG 16 days till Congres goes home. Now or never for Cassidy/Carter skin sub bills.

1 · Reply

RUDYRUDY Dec. 3 at 9:13 PM

$MDXG Dec 20, Congress shuts down. Race is on for Cassidy/Carter bills.

0 · Reply

SuperGreenToday Dec. 3 at 11:04 AM

0 · Reply

ta99bobotw Dec. 2 at 2:54 PM

$MDXG ... the market doesn't seem to be all that optimistic about MDXG taking market share starting in January. Was hoping we'd have seen a bit of price increase by now in anticipation.

2 · Reply

BEATOFtheMARKET Dec. 2 at 2:32 AM

$MDB $MDBX $MDXG $MEC $MEDP

0 · Reply

biomaster22 Dec. 2 at 1:00 AM

2 · Reply

RUDYRUDY Dec. 1 at 11:13 PM

$MDXG Stuck in bad chart-ville again. Sheesh.

0 · Reply

GlobalInsights Dec. 1 at 8:52 PM

0 · Reply

GlobalInsights Dec. 1 at 8:52 PM

$MDXG Part 1 from date of hire. The Company also announced that the Compensation Committee of the Board of Directors of the Company approved inducement awards under Nasdaq Listing Rule 5635(c)(4) consisting of 3,300,000 performance stock units (“PSUs”) and a non-qualified stock option (“Option”) to purchase 3,600,000 shares of the Company’s common stock with an exercise price equal to $3.70 per share (the closing price per share of the Company’s common stock as reported on the NASDAQ on January 27, 2023) as a material inducement to his hiring as Chief Executive Officer of the Company.

0 · Reply

Quantumup Dec. 1 at 12:18 PM

Mizuho🏁 $AXGN Outperform/$40 $SYK $BAX $IART $MDXG Mizuho said—Our OP rating on AXGN is predicated on: 1) favorable setup into the upcoming BLA PDUFA date (Dec 5) where we expect a positive outcome, 2) core extremity channel checks that point toward a potential +10% uplift in Avance utilization post-BLA approval, 3) Mizuho Americas November 2025 breast survey findings that forecasts Avance mix in reconstruction surgeries to increase +30% over the next two years, 4) untapped upside opportunity in breast augmentation where nerve injury incidence sits in 10-15% range, and 5) attractive call option in prostate cancer that could drive +$100MN of incremental peak sales (+35% uplift to 2026 base). Our $40 PT prices AXGN shares at 5.0x our blended 2-year sales outlook ('26E-'27E) while our $50 bull case contemplates higher share-capture scenarios in Breast & Prostate.

0 · Reply

sage70 Nov. 28 at 4:32 PM

$MDXG My point is J Capper will not be the one who decides when, to whom, & for how much MDXG is sold. It will be the two EW board members & their ability to persuade BoD to their POV. Given his age, this is Capper's capstone/ significant Med Tech CEO ship & he will make a bundle on MDXG. But these guys are ALL rich already & they won't sell until it meets all of their needs. Read this from '24 Report: "Risks Related to the Ownership of Our Common Stock-EW Healthcare Partners & its interests may conflict with those of our other shareholders. Certain provisions of Florida law & anti-takeover provisions in our organizational documents may discourage or prevent a change of control.Certain provisions of Florida law & anti-takeover provisions in our organizational documents may discourage or prevent a change of control, even if an acquisition would be beneficial to shareholders, which could affect our share price adversely & prevent attempts by shareholders to remove current management."

2 · Reply

sage70 Nov. 28 at 4:17 PM

$MDXG To Global-- As I remember, you were an employee of Medtronic, & from your posts re: MDXG & BSEM, you have an understanding of Med Device orgs & their operations I do not possess. But IF you read the 2024 MDXG Annual Report, you'll see JC's vesting of his PSU package is dependent on performance. I doubt anyone on the BoD or JC expected, when he was hired in Jan '23, the stock price would be in mid 6's. From report: "The CEO Performance PSUs vest on the basis of achieved revenue growth, while CEO Performance Option vests on the basis of share price appreciation. The occurrence & extent of vesting depends on Company’s compound annual growth rate (“CAGR”) achieved w/ respect to its revenue growth between the year ended December 31, 2022 & the year ending December 31, 2026. The PSUs may vest w/ respect to 50% to 200% of the granted number of PSUs, depending on extent of CAGR achievement. Failure to achieve the CAGR associated with 50% of achievement would result in no vesting.

1 · Reply

sage70 Nov. 26 at 6:26 PM

$MDXG Both of you, like me, are longtime MDXG shareholders & not paid shorts, who used to plague Mimedx & to a lesser degree this message board- so no need for me to go private w/ either of you. Med Device & Biotech healthcare companies are 2 different beasts with different R.O.I. strategies. The EW MDXG board members are med device guys, who 'saved' the company during its most perilous period w/ $150 million at $3.89 per share & credit deals etc. When KOA trial misfired, they freaked & reverted to what they know. Read the Annual Report of 2 years ago, it was clear they were dumping the KOA regen med Biotech path. Now as a med tech co. CEO J Capper will grind it out w/ regulation, pricing limitations & commoditization. The BoD, in the meantime, has doubled down on being legally protected from shareholder lawsuits. WE WILL make money eventually because of dHACM's intrinsic value & Capper's execution; but there will be other considerations @ sale, made by the BoD, beside share price.

2 · Reply

sage70 Nov. 26 at 5:36 PM

$MDXG If you have not done so already, I urge you to read carefully the two previous MDXG Annual Shareholder Reports; especially as to EW's assertion of its legal right to pursue material interests that directly conflict w/ material interests of common stock shareholders, including when opportunities may arise for a 'change of control', where EW asserts it has the right to persuade the Board to refuse a sale of the company even if that acquisition price would benefit common stock shareholders. EW has controlling or partial interest in numerous regen med companies, & they have packed the MDXG Board, & have their thumb on the scale. All that being true & a matter of public record, EW has investors in ITS funds they have to satisfy w/ their MDXG investment. I predict (parsed from his public spoken comments etc) when Capper gets revenues to $500 million per annum, the BoD will entertain offers & not before. Capper is a med device turnaround CEO; that is why he was hired & what he is doing.

1 · Reply

jmdaddy Nov. 26 at 4:28 PM

$MDXG With extra cash could a share buy back from EW happen? It would reduce the outstanding shares and raise the share price. I seem to recall a 5 year time frame about EW commitment when they first bought shares.

1 · Reply

CharlyBue Nov. 26 at 2:59 PM

$MDXG a buyout is in talk I mean trigger is $7 since years, maybe 10% premium - $7.70 - I think it isn‘t worth sitting here and waiting

1 · Reply

BEATOFtheMARKET Nov. 25 at 8:17 PM

$MDB $MDBX $MDXG $MEC $MEDP

0 · Reply

RUDYRUDY Nov. 25 at 4:05 AM

$MDXG Prediction: Cassidy/Carter bills will get passed, flip the middle finger to CMS & Oz, and turbo charge Mimedx sales

1 · Reply

WayneProv3 Nov. 25 at 12:56 AM

$MDXG What about us? Lolol....

2 · Reply

WayneProv3 Nov. 25 at 12:56 AM

$MDXG Solventum to buy Acera Surgical for up to $850M, repurchase $1B in stock https://share.google/dYTeHc8lxUO2uOMPT

2 · Reply

Market Cap	1.03B
Revenue (ttm)	348.88M
Net Income (ttm)	42.42M
EPS (ttm)	N/A
PE Ratio	18.05
Forward PE	18.80
Profit Margin	12.16%
Debt to Equity Ratio	0.01

Volume	527,600
Avg Vol	878,400
Day's Range	N/A - N/A
Shares Out	148.10M
Stochastic %K	70%
Beta	1.64
Analysts	Strong Sell
Price Target	$12.20